[ABCD-10 scale as a predict of mortality in children with severe pharmacodermias. Case report]

Britza Barrios-Díaz1, Ana Paola Macías-Robles2, Héctor Hugo Campos-Téllez2

  • 1Servicio de Alergia e Inmunología Clínica Pediátrica, Hospital de Pediatría, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México. bribadi@hotmail.com.

Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
|August 11, 2023
PubMed

Insights

Severe pharmacodermias (SF) carry high mortality risks, especially in children with chronic kidney failure (CKD) on dialysis. The ABCD-10 scale may better predict mortality in these cases than SCORTEN.

Area of Science:

  • Pharmacology
  • Nephrology
  • Pediatrics

Background:

  • Severe pharmacodermias (SF) are linked to significant morbidity and mortality.
  • Chronic kidney failure (CKD) requiring dialysis is a key factor in increased mortality risk.
  • The ABCD-10 scale, incorporating dialysis history, is a predictive mortality tool.

Observation:

  • A 2-year-old male with CKD on peritoneal dialysis and Lennox-Gastaut syndrome developed Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-NET) after phenytoin administration.
  • The patient experienced acute peritonitis and septic shock, with treatment including immunoglobulin and systemic steroids proving ineffective.
  • The case resulted in a fatal outcome.

Findings:

  • The ABCD-10 scale demonstrated a higher mortality prediction compared to SCORTEN in this case, attributed to the patient's dialysis history.
  • Currently, no validated pediatric mortality prediction scales exist for severe pharmacodermias.
  • Dialysis history appears to be a critical factor in mortality prediction for pediatric SF.

Implications:

  • This case highlights the limitations of existing scales like SCORTEN in pediatric severe pharmacodermias.
  • There is a critical need to develop specific, validated mortality prediction scales for children experiencing severe pharmacodermias.
  • Further research should focus on identifying unique risk factors for mortality in pediatric SF patients to inform scale development.
Abstract